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Summary
 
The chemokines are a large group of chemotactic cytokines that regulate leukocyte trafficking
and have recently been shown to inhibit human immunodeficiency virus entry into cells. Eo-
taxin is a C–C chemokine implicated in the recruitment of eosinophils in a variety of inflam-
matory disorders and, unlike all other eosinophil chemoattractants, is eosinophil specific. How-
ever, given the large number of chemoattractants that have activities on eosinophils, it is
unclear whether eotaxin has an important role in vivo. Furthermore, it remains unclear why
there is constitutive expression of eotaxin in healthy states in the absence of eosinophilic in-
flammation. To begin to determine the significance of eotaxin at baseline and during eosino-
phil-mediated disease processes, we have used targeted gene disruption to generate mice that
are deficient in eotaxin. Such mice demonstrate that eotaxin enhances the magnitude of the
early (but not late) eosinophil recruitment after antigen challenge in models of asthma and stro-
mal keratitis. Surprisingly, a role for eotaxin in regulating the constitutive number of eosino-
phils in the peripheral circulation is also demonstrated. These results indicate a contributory
role for eotaxin in the generation of peripheral blood and antigen-induced tissue eosinophilia.
 
E
 
osinophils are potent pro inflammatory cells involved
in the pathogenesis of several human disorders such as
asthma and chronic parasitic infections (1). A better under-
standing and treatment of these diseases involves elucidating
the mechanisms that regulate the selective accumulation
of eosinophils. The generation of tissue eosinophilia in-
volves multiple processes, including eosinophil hematopoi-
etic development, endothelial adhesion, chemotaxis, and sur-
vival. Whereas eosinophil growth factors, such as IL-5, are
involved in eosinophil hematopoiesis and survival, adhe-
sion and locomotion are predominantly controlled by che-
moattractants.
The chemokines are a super family of chemotactic cy-
tokines that mediate leukocyte trafficking by binding to
specific G protein linked seven transmembrane spanning re-
ceptors (2). Recently, chemokine receptors have been iden-
tified as coreceptors for HIV entry into cells and chemo-
kines have been shown to be inhibitors of HIV replication
(3). Chemokines are divided into three groups based on the
primary sequence of the first two cysteines: the C–X–C,
C–C, and C families. Whereas the C–X–C and C families
are mainly active towards neutrophils and lymphocytes, re-
spectively, the C–C family members are active towards
macrophages, lymphocytes, basophils, and eosinophils. The
eosinophil active chemokines include RANTES, macro-
phage chemotactic protein (MCP)-2, MCP-3, MCP-4, mac-
rophage inflammatory protein (MIP)-1
 
a
 
, and eotaxin (4).
Eotaxin is the chief eosinophil chemotactic activity released
into the lung in a guinea pig model of eosinophilic airway
hypersensitivity (5) and its mRNA is induced in multiple
animal models of eosinophilic inflammation and in human
tissue in response to allergen challenge (6–12). When eo-
taxin is delivered to experimental animals in vivo, it in-
duces a potent and rapid eosinophil-specific recruitment that
is augmented by IL-5 (13, 14). However, eotaxin may have
other activities given that its mRNA is constitutively ex-
pressed at high levels in multiple tissues in the absence of
eosinophilic inflammation (6–8, 10), it has weak macro-
phage chemoattractive activity at high doses in vitro (8), its
receptor is expressed at low levels in other activated leuko-
cytes (15), and eotaxin can inhibit the replication of certain
HIV strains in vitro (16). However, the role of eotaxin dur-
ing eosinophil-mediated disease states is not known. If the
activity of eotaxin is indeed restricted to eosinophils, then
interference with its function would have clinical utility
provided that the other chemoattractants do not have re-
dundant activity. Using a gene disruption strategy, two
other chemokines have been demonstrated to have nonre-
dundant roles: MIP-1
 
a
 
 in the pathogenesis of viral induced
inflammation (17) and stromal cell–derived factor-1 in B cell
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lymphopoiesis and myelopoiesis (18). To explore further the
function of eotaxin, we have used gene targeting to create
mice with a genetic deficiency in eotaxin.
 
Materials and Methods
 
Targeting and Generation of Eotaxin-disrupted Mice.
 
An eotaxin-
targeting construct (Fig. 1 
 
A
 
) was constructed by cloning a 5
 
9
 
fragment containing a 5.0-kb NotI–XhoI fragment and a 3
 
9
 
 frag-
ment containing a 3.0-kb EcoRV–Xba I fragment into a vector
(pPNT) that contained a neomycin-resistant gene (PGK–
 
neo
 
) and
a herpes simplex virus thymidine kinase (HSV–
 
TK
 
) gene in tan-
dem. The vector was linearized and transfected into TC1 embry-
onic stem cells (19) and 10
 
5
 
 resistant clones were screened by
Southern blot analysis using a 1.4-kb StuI–XbaI probe (Fig. 1 
 
A
 
);
four positive clones were detected. Two targeted clones were in-
jected into C57BL/6J blastocysts by standard methods. Both
clones produced high degree chimeras, which transmitted the dis-
rupted eotaxin allele to offspring at high frequency, allowing this
allele to be established in a mixed background (129SvEv 
 
3
 
 NIH
Black Swiss Webster). Siblings from mixed heterozygote matings
were used to control for strain background effects. All mice were
housed in a germ-free barrier facility.
Genotyping was performed by Southern blot analysis of tail
DNA using the 1.4-kb probe described above. For Northern anal-
ysis, total RNA was isolated using Trizol Reagent (GIBCO BRL,
Gaithersburg, MD) and 20 mcg was electrophoresized into agar-
ose, transferred to Gene Screen (Dupont–New England Nuclear,
Boston, MA), and hybridized with a full-length murine eotaxin
cDNA or a 28S rRNA cDNA (7).
 
Hematological Analysis.
 
Tail or retro orbital vein blood sam-
ples were placed into EDTA containing tubes and subjected to
automated cell counting. Peripheral smears were stained with
Wright-Giemsa and analyzed at 1,000
 
3
 
 for the cell differential by
an observer unaware of each genotype. For flow cytometric anal-
ysis, splenocytes or thymocytes were stained with antibodies and
subjected to flow cytometry in a Cytofluorograph II flow cytom-
etry machine (Ortho Diagnostic Systems, Inc., Raritan, NJ). The
FITC-conjugated monoclonal antibodies were the following: rat
anti–mouse B220, CD3, CD5, CD8, CD18, CD23, CD24,
T200, and Gr-1; PE-conjugated monoclonal antibodies were rat
anti–mouse T cell receptor 
 
gd
 
 and CD4; FITC-conjugated goat
polyclonal antiserum were anti-mouse IgM and Ig
 
k
 
; and FITC–
hamster anti–mouse was anti-T cell receptor 
 
ab
 
. Additionally,
unlabeled primary mAbs were rat anti–mouse Mac-1, FcR
(2.4G2), PgP-1, Mel 14, and VLA-4, which were used with sec-
ondary FITC-labeled goat anti–rat IgG.
 
Experimental Allergic Airway Disease.
 
The airway sensitization
protocol has been previously described (20). Mice were immu-
nized intraperitoneally with 10 mcg of OVA (Sigma Chemical Co.,
St. Louis, MO) and 1 mg aluminum hydroxide intraperitoneally
on days 0, 7, and 14. Sham-immunized mice received aluminum
hydroxide alone. Mice underwent aerosol challenge with OVA
(50 mg/ml in sterile saline) 7–10 d after the final immunization.
Bronchoalveolar lavage (BAL) analysis was performed at either 18
or 48 h after aerosol challenge.
 
Experimental Onchocercal Keratitis.
 
Mice were sensitized to sol-
uble parasite antigens (OvAg) by 4 weekly s.c. immunizations
with 10 mcg OvAg together with STP adjuvant as previously de-
scribed (21). For intracorneal challenges, 1 wk after the final sen-
sitization, 10 mcg OvAg was injected into the corneal stroma of
the right eye; in some experiments, OvAg was injected in the
contralateral corneas 1 d before killing, thereby providing tissue
from day 1 and 8 after challenge. Rabbit antisera to murine eosin-
ophil major basic protein was a gift of Dr. G. Gleich of the Mayo
Clinic (Rochester, MN) and used to detect tissue eosinophils.
Statistical differences between groups were determined by the
Student’s 
 
t
 
 test.
 
Thioglycollate-induced Peritoneal Inflammation.
 
Mice were injected
intraperitoneally with 1.0 ml of 2.9% (wt/vol) thioglycollate and
the peritoneal cells analyzed after 48 h as previously described (7).
 
Results and Discussion
 
Generation of Eotaxin Null Mice.
 
The eotaxin gene is com-
posed of three exons: exon 1 encodes the leader sequence,
exon 2 encodes most of the mature protein, and exon 3 en-
codes predominantly untranslated mRNA (7). To disrupt
the eotaxin gene, a targeting strategy was employed that
deleted 1.4 kb of DNA corresponding to all of exon 2 and
most of exon 3 (Fig. 1 
 
A
 
) and thus producing a null muta-
tion. Clones that underwent homologous recombination
were screened by Southern blot analysis using the 1.4-kb 3
 
9
 
probe. Two targeted clones were injected into blastocysts,
and both transmitted the disrupted eotaxin allele in the germ-
line of mice. Animals with a mixed background were gen-
erated by mating chimeras with NIH Black Swiss Webster
mice. No phenotypic variance was detected between the
two different knockout lines.
Figure 1. Generation of eotaxin-disrupted mice. Shown in (A) is the
eotaxin genomic locus, the targeting vector, and the targeted null locus.
Vertical rectangles represent exons; black regions in the exons are deleted
by the targeting strategy. The targeting vector contains a neomycin-resis-
tant gene (neo) and a herpes simplex virus thymidine kinase (HSV–TK)
gene in tandem. In (B), Southern analysis of BamHI-digested genomic
DNA from the offspring of a heterozygous cross. Wt and null indicate
wild-type and targeted locus, respectively. (C) shows a Northern analysis
of skin total RNA (20 mcg) from homozygote null (2/2), heterozygote
(1/2), and wild-type mice (1/1). The Northern blot was hybridized
with a full-length murine eotaxin cDNA or 28S rRNA probe. Restric-
tion enzyme abbreviations: N, NotI; B, BamHI; Xh, XhoI; R5, EcoRV;
X, XbaI. 
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F1 heterozygous offspring were intercrossed, and F2 off-
spring were genotyped by Southern blot analysis. All three
genotypes were detected in F2 litters (Fig. 1 
 
B
 
). Cumula-
tive genotyping of heterozygous crosses from mixed back-
ground matings revealed that the ratios of wild-type/het-
erozygote/homozygote mutant mice were 45:91:55. These
ratios were not different from the expected 1:2:1 Mende-
lian ratios, indicating that the eotaxin gene disruption did
not affect viability. This is in contrast with the gene target-
ing of another chemokine stromal cell–derived factor-1,
which resulted in perinatal lethality (18).
The mouse skin is normally a rich source of eotaxin
mRNA constitutively. To verify that the eotaxin targeting
strategy had generated a true eotaxin gene disruption, eo-
taxin mRNA was examined by Northern blot analysis of
skin RNA. Wild-type and heterozygote mice had mRNA
of the predicted size; in contrast, eotaxin-targeted mice had
no detectable eotaxin mRNA (Fig. 1 
 
C
 
). This indicated
that the targeting strategy had indeed generated eotaxin
null mice.
 
Hematological and Lymphoid Analysis.
 
One of the char-
acteristic features of eotaxin that remains puzzling is its wide-
spread (although not ubiquitous) constitutive expression in
various tissues, especially lymphoid tissue (thymus and lymph
node). It has been postulated that constitutive eotaxin might
affect eosinophil and/or lymphocyte homing into these tis-
sues (6). Therefore it was of interest to examine various or-
gans and their resident leukocyte populations. Peripheral
blood analysis revealed no abnormalities in the total leuko-
cyte, red blood cell, and platelet counts, or white blood cell
differential in eotaxin null mice compared with wild type
mice (data not shown). In contrast, the total eosinophil
count was significantly reduced (
 
P
 
 
 
5
 
 0.007) in the knock-
out mice compared with wild-type mice (Fig. 2). Wild-
type mice and null mice had 243 
 
6
 
 43 (mean 
 
6
 
 SEM, 
 
n
 
 
 
5
 
12) and 69 
 
6
 
 22 (
 
n
 
 
 
5
 
 13) eosinophils/mm
 
3
 
 of blood, re-
spectively. Analysis of bone marrow cells revealed no dif-
ferences in the eosinophil lineage (data not shown). This
indicated that eotaxin was unlikely to be stimulating eosi-
nophil hematopoiesis as might have been expected based
on the ability of other chemokines (e.g., MIP-1
 
a
 
, IL-8) to
regulate hematopoiesis (22).
No gross or histological abnormalities were detectable in
any organ, including those with abundant eotaxin expres-
sion (skin, thymus, heart, and intestine) (7). The leukocytes
from the thymus and spleen from four wild-type and eo-
taxin null mice were subjected to flow cytometry analysis
for cell surface and activation markers (data not shown).
No abnormalities were seen in leukocyte phenotype using
lymphocyte markers that included B220, Thy1, CD3, CD4,
CD8, and CD23; additionally, no abnormalities were de-
tected in adhesion molecules including CD18, VLA-4, or
PgP-1. Thus, the function of constitutive eotaxin does not
appear to affect the number or phenotype of thymocytes or
splenocytes. The only apparent effect of eotaxin deficiency
was therefore on the baseline number of eosinophils in the
peripheral blood.
 
Eosinophil Recruitment into Allergic Airways.
 
Eotaxin has
Figure 2. Eosinophil count in the peripheral blood of naive mice. The
absolute eosinophil count in the peripheral blood is shown for wild-type
(1/1) and eotaxin null (2/2) mice. The results are expressed as mean 6
SEM for 1/1 (n 5 12) and 2/2 (n 5 14); P 5 0.007.
Figure 3. Allergen induced airway eosinophilia. Mice were sensitized
systemically to OVA and underwent inhaled OVA challenge. At 18 h af-
ter allergen challenge, the lungs were assessed for eotaxin mRNA expres-
sion (A) and the eosinophil count in the bronchoalveolar fluid (B).
Northern blot analysis of total RNA evaluating eotaxin expression in eo-
taxin null (2/2) and wild-type mice (1/1). The hybridization of a 28S
rRNA cDNA probe is also shown. Each lane represents a different
mouse. In (B), the number of eosinophils in the lung fluid is shown as
mean 6 SEM for wild-type (n 5 10), eotaxin null (n 5 13), or control
unsensitized mice (n 5 3); P 5 0.005 between 1/1 and 2/2. 
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been implicated in the recruitment of eosinophils into the
lungs following allergen challenge (5, 6, 11). Therefore, it
was important also to determine whether the deletion of
eotaxin affected the recruitment of eosinophils into the
lung during experimental allergic airway disease. When
mice are sensitized to intraperitoneal OVA and then chal-
lenged with inhaled OVA, eotaxin lung mRNA is known
to be induced rapidly (with peak expression at 3–6 h) and is
accompanied by the development of an eosinophil-depen-
dent allergic airway disease (6, 11, 20). At 18 h after aller-
gen challenge, eotaxin mRNA was readily detectable in the
lungs of wild-type mice, but not detectable in eotaxin null
mice (Fig. 3 
 
A
 
). This confirmed that the eotaxin gene was
indeed inactivated. At 18 h after the allergen challenge, the
number of cells in the BAL fluid was assessed. No signifi-
cant differences in the lymphocyte, neutrophil, or mac-
rophage cell counts were detectable (data not shown).
However, eosinophil numbers were reduced by 70% in the
eotaxin null mice compared with identically treated wild-
type mice (6.6 
 
6
 
 1.7 
 
3
 
 10
 
4
 
 versus 2.1 
 
6
 
 0.5 
 
3
 
 10
 
5
 
, re-
spectively, 
 
P
 
 
 
5
 
 0.005) (Fig. 3 
 
B
 
). This observation demon-
strated that eotaxin was important in the early recruitment
of eosinophils to the lungs in this model.
It is noteworthy that eotaxin null mice still mounted an
eosinophil response compared with unsensitized control mice
(Fig. 3 
 
B
 
), indicating the importance of other chemoattrac-
tants. The production of chemoattractants during an inflam-
matory response is a complicated dynamic process. Whereas
resident epithelial cells appear to be the primary source of
eotaxin and other chemokines at baseline and during the
early part of the late phase inflammatory response, infiltrat-
ing cells including macrophages and eosinophils can also pro-
duce significant amounts of chemokines (10, 23). There-
fore, we were interested in determining the role of eotaxin
at a later time in the inflammatory response. At 48 h after
antigen challenge, there was no longer a reduced number
of eosinophils in the BAL fluid of eotaxin null mice com-
pared with wild-type mice (data not shown). The role of
eotaxin in this model appears to coincide with the peak in-
duction of eotaxin mRNA at 3–6 h after antigen challenge
(6, 11, 20).
 
Eosinophil Recruitment into Inflamed Corneas.
 
Eosinophils
also accumulate in other tissues besides the lungs, particu-
larly during parasitic infections. Therefore, it was of inter-
est to determine whether a role for eotaxin could be dem-
onstrated in other inflammatory models. Inflammation of
the corneal stroma (stromal keratitis) is a serious complica-
tion of infection with the nematode parasite Onchocerca vol-
vulus and is a major cause of blindness (River Blindness) in
Africa and Latin America. After sensitization with parasite
antigens in mice, intracorneal antigen challenge induces
pronounced corneal inflammation associated with infiltra-
tion of the cornea by eosinophils (21). The severity of
corneal pathology is correlated with the local expression of
chemokines including eotaxin (12). Wild-type and eotaxin
null mice were immunized s.c. and then injected intracor-
neally with O. volvulus antigens. No difference was noted in
the number of total cells in the cornea of wild-type and eo-
taxin null mice 1 d after antigen injection (mean 6 SEM/
corneal section was 870 6 90 versus 865 6 44, respec-
tively; P 5 0.97). In contrast, the number of eosinophils in
the corneal stroma of eotaxin null mice was significantly less
than in wild-type mice (105 6 21 versus 204 6 36 eosino-
phils/section; P 5 0.02) (Fig. 4). To determine whether
this reduction persisted at later times after antigen chal-
lenge, the eosinophil recruitment 8 d after O. volvulus anti-
gen challenge was examined. Both groups of mice now had
comparable numbers of eosinophils. Eosinophils numbers
were 340 6 60 and 440 6 55 (P 5 0.26) for wild-type and
eotaxin null mice, respectively. These data indicate that eo-
taxin is important in early recruitment of eosinophils to the
cornea during experimental helminth-mediated keratitis.
Cell Recruitment into the Peritoneal Cavity in Response to a
Nonspecific Inflammatory Trigger. Because all C–C chemokines
described have activities for macrophages and eotaxin has
weak macrophage chemotactic activity in vitro (8), it was
important to examine further the specificity of eotaxin in a
model of inflammation known to induce macrophage re-
cruitment. Inflammation in the peritoneal cavity was in-
duced by the injection of a nonspecific inflammatory trig-
ger, thioglycollate. At 48 h after injection, cells recovered
from the peritoneal lavage were composed of 90% mac-
rophages in both wild-type and knockout mice with the
recovery of 1.1 6 0.1 3 107 and 1.2 6 0.05 3 107 mac-
rophages/mouse (mean 6 SEM, n 5 5), respectively, indi-
cating that eotaxin had no role in macrophage recruitment
in this model. There were no differences in the other 10%
of the leukocytes recruited (data not shown).
The generation of eotaxin null mice has revealed several
important biological properties of eotaxin. First, a defini-
tive role for eotaxin in enhancing the magnitude of early
eosinophil tissue recruitment after antigen challenge via
Figure 4. Antigen-induced corneal eosinophilia. Wild-type and eo-
taxin null mice received four subcutaneous immunizations with antigens
from the parasitic helminth O. volvulus. Animals were subsequently in-
jected intracorneally with parasite antigen and sacrificed 1 d later. 5-mm
sections of the cornea were immunostained with rabbit sera to eosinophil
major basic protein and eosinophils in the corneal stroma were counted.
Data are shown as mean 6 SEM for wild-type (n 5 13) and eotaxin null
(n 5 14) mice with differences between groups being significant (P 5
0.02).789 Rothenberg et al. Brief Definitive Report
two different routes of antigen exposure (mucosal and epi-
thelial) is demonstrated. These two systems are likely to in-
volve the generation of a large number of chemoattractants
and to use diverse types of antigen-presenting cells. It
should be pointed out that even in the absence of eotaxin,
there is still abundant antigen-induced tissue eosinophilia,
indicating an important role for other eosinophil chemoat-
tractants. Eosinophils use two distinct chemokine recep-
tors: C–C chemokine receptor-1 (CCR-1) and CCR-3 (9,
15, 24). Whereas CCR-3 is more highly restricted to eosin-
ophils and binds eotaxin, RANTES, MCP-3, and MCP-4;
CCR-1 is expressed by other leukocytes and binds MIP-1a,
MCP-3, and RANTES. Pharmacological blockade of eosin-
ophilia therefore might interfere with chemokine receptor
signal transduction in addition to blockade of eotaxin. In
support of this, MIP-1a has been shown to be partially re-
sponsible for eosinophil lung recruitment in response to a
Schistosoma mansoni antigen (25). Additionally, other chemoat-
tractants besides chemokines (e.g., LTB4) appear to be in-
volved in eosinophil lung recruitment (26). Second, eo-
taxin is demonstrated to be eosinophil specific, because
only eosinophils are reduced in the eotaxin null mice. Pre-
vious specificity studies were based on in vitro assays or ad-
ministration studies in vivo. And third, eotaxin is found to
exert an effect on the baseline level of eosinophils in the
peripheral circulation. This effect does not appear to be
mediated at the level of the bone marrow, suggesting that
there is an alteration in eosinophil trafficking in the absence
of eotaxin. While the mechanism of eosinophil growth and
development has been extensively studied and found to
predominantly depend upon IL-5 (27), little is understood
concerning the involvement of eotaxin in the generation of
circulating eosinophils. It is noteworthy that IL-5 null mice
still have residual eosinophils, indicating the importance of
other pathways in the generation of eosinophilia (27). Eo-
taxin gene-targeted mice should provide a useful genetic
model to understand further the mechanism of baseline and
antigen-induced eosinophilia.
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